Background: BAL4815 is the active component of the new azole antifungal agent BAL8557 entering phase III clinical development. This study was conducted to compare the in vitro activity of BAL4815 and five other antifungal agents against 296 Candida bloodstream isolates.
Methods: Candida isolates were recovered consecutively from blood cultures between 1995 and 2004. Microdilution testing was done in accordance with CLSI / NCCLS guideline M27-A2 in RPMI 1640 MOPS broth. Plates were incubated at 35°C for 24- 48 hours. The antifungal agents tested were amphotericin B (AMB), flucytosine (5FC), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), and BAL4815.
Results: C. albicans was the most common species, with 57.1% of all isolates. There was no trend found in favor of nonalbicans Candida spp. over time. In terms of MIC50s, BAL4815 was more active (0.004 mg/L) than ITC (0.008 mg/L), VRC (0.03 mg/L), 5FC (0.125 mg/L), AMB (0.5 mg/L), and FLC (8 mg/L). For BAL4815, MIC50s/MIC90s ranged from 000.2/0.004 mg/L for C. albicans to 0.25/0.5 mg/L for C. glabrata. 2% of isolates (C. glabrata and C. krusei) were resistant to FLC; C. albicans strains resistant to FLC were not detected. The frequency of isolates with MICs for BAL4815 that were >0.5 mg/L was 0.7%.
- ICAAC 46th